Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with ...

In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a leading cause of kidney transplant loss, with approximately ...

Biogen (BIIB) announced the initiation of dosing in the global clinical study, TRANSCEND. The Phase 3 study will evaluate the efficacy and ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

Biogen Inc. (NASDAQ: BIIB) has steadily declined since peaking ... which includes Phase 3 trials for Felzartamab, a treatment for multiple myeloma and kidney diseases. Viehbacher commented, “So, you ...

Markets are tanking on tariff fears, inflationary concerns and now fears of recession. “Given this is so uncertain and that ...

Biogen remains focused on advancing its immunology and rare disease pipeline, including three Phase 3 trials for Felzartamab in 2025. Q4 non-GAAP diluted EPS was $3.44 compared to analysts ...

Litfilimab did not garner a mention on Biogen's earnings call, no data was shared in relation to felzartamab, and pegol was described as "only the third agent with a positive global Phase III ...

Biogen Inc. (NASDAQ ... which includes Phase 3 trials for Felzartamab, a treatment for multiple myeloma and kidney diseases. Viehbacher commented, “So, you know, the race really that we are ...

Biogen Inc. (NASDAQ:BIIB ... but I think we feel particularly excited about Felzartamab and the potential that this could have in rare kidney disease. And of course, then we have a whole phase ...

Biogen Inc. BIIB has steadily declined since ... which includes Phase 3 trials for Felzartamab, a treatment for multiple myeloma and kidney diseases. Viehbacher commented, “So, you know, the ...